81 results
8-K
EX-99.1
AGRX
Agile Therapeutics Inc
15 May 24
Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:15pm
unrealized gains or losses pertaining to liability classified warrants. We believe that the presentation of these non-GAAP financial metrics provides useful
8-K
EX-99.1
AGRX
Agile Therapeutics Inc
28 Mar 24
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
9:06am
unrealized gains or losses pertaining to liability classified warrants and one-time non-cash charges incurred in connection with the loss on disposition
8-K
EX-99.1
unisj2zaep2nc
9 Nov 23
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
8:15am
8-K
EX-99.1
ui6z9t43gz6evh422
9 Aug 23
Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8:10am
S-8
EX-99.1
te5fzfac tk6avrbilc
9 Jun 23
Registration of securities for employees
5:19pm
424B4
jet4pg1qraqn xy47
24 May 23
Prospectus supplement with pricing info
4:05pm
8-K
EX-99.1
tvpckbowc
11 May 23
Agile Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:15pm
424B5
u8c vek35
23 Aug 22
Prospectus supplement for primary offering
4:30pm